Increased kallistatin levels in patients with obesity and prediabetes compared to normal glucose tolerance

References

• Shaw JE, Zimmet PZ, de Courten M, et al. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 1999; 22:399–402.
   PubMed Web of Science ®Google Scholar
• de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn study. JAMA 2001;285:2109–2113.
   PubMed Web of Science ®Google Scholar
• The DECODE Study Group. European Diabetes Epidemiology Group. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 1999;354:617–621.
   PubMed Web of Science ®Google Scholar
• The DECODE Study Group. Is the current definition for diabetes relevant to mor tality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688–696.
   PubMed Web of Science ®Google Scholar
• Ning F, Tuomilehto J, Pyorala K, Onat A, Soderberg S, Qiao Q. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care 2010;33:2211–2216.
   PubMed Web of Science ®Google Scholar
• Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: A systematic review of the evidence. J Am Coll Cardiol 2010;55(13):1310–1317.
   PubMed Web of Science ®Google Scholar
• Chao J, Chai KX, Chen LM, et al. Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem 1990;265:16394–16401.
   PubMed Web of Science ®Google Scholar
• Miao RQ Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002;100:3245–3252.
   PubMed Web of Science ®Google Scholar
• Wolf WC, Harley RA, Sluce D, Chao L, Chao J. Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem 1999;47:221–228.
   PubMed Web of Science ®Google Scholar
• Chao J, Yin H, Yao YY, Shen B, Smith RS Jr., Chao L. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther 2006;17:1201–12137.
   PubMed Web of Science ®Google Scholar
• McBride JD, Jenkins AJ, Liu X, Zhang B, Lee K, Berry WL, Janknecht R, Griffin CT, Aston CE, Lyons TJ, Tomasek JJ, Ma JX. Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Invest Dermatol 2014;134(6):1725–1734.
   PubMed Web of Science ®Google Scholar
• Jenkins AJ, McBride JD, Januszewski AS, et al. Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res 2010;2:19.
   PubMedGoogle Scholar
• El-Asrar MA, Andrawes NG, Ismail EA, Salem SM. Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: Relation to carotid intima media thickness. Vasc Med 2015;20(6):509–517.
   PubMed Web of Science ®Google Scholar
• Arancibia C, Galgani J, Valderas JP, Morales M, Santos JL, Pollak F. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Rev Med Chil 2014;142(9):1106–1112.
   PubMed Web of Science ®Google Scholar
• Ascaso J, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26(12):3320–3325.
   PubMed Web of Science ®Google Scholar
• Ascaso JF, Romero P, Real TJ, Priego A, Valdecabres C, et al. Insulin resistance quantification by fasting insulin plasma values and HOMA index in non diabetic population. Med Clin (Barc) 2001;117:530–533.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640–1645.
   PubMed Web of Science ®Google Scholar
• Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004; 164(19):2147–2155.
   PubMedGoogle Scholar
• Zhou S, Sun Y, Zhuang Y, Zhao W, Chen Y, Jiang B, Guo C, Zhang Z, Peng H, Chen Y. Effects of kallistatin on oxidative stress and inflammation on renal ischemia-reperfusion injury in mice. Curr Vasc Pharmacol 2015;13(2):265–273.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bledsoe G, Hagiwara M, Shen B, Chao L, Chao J. Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 2012;303(8):F1230–F1238.
   Google Scholar
• Gao L, Li P, Zhang J, Hagiwara M, Shen B, Bledsoe G, Chang E, Chao L, Chao J. Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc 2014;3(5):e001194.
   Google Scholar
• Yin H, Gao L, Shen B, Chao L, Chao J. Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension 2010;56(2):260–267.
   PubMed Web of Science ®Google Scholar
• Yiu WH, Wong DW, Wu HJ, Li RX, Yam I, Chan LY, Leung JC, Lan HY, Lai KN, Tang SC. Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress. Kidney Int 2016;89(2):386–398.
   Google Scholar
• Liu X1, Zhang B, McBride JD, Zhou K, Lee K, Zhou Y, Liu Z, Ma JX. Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes 2013;62(12):4228–4238.
   PubMed Web of Science ®Google Scholar